These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 12829905)

  • 1. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study.
    Husain S; Tollemar J; Dominguez EA; Baumgarten K; Humar A; Paterson DL; Wagener MM; Kusne S; Singh N
    Transplantation; 2003 Jun; 75(12):2023-9. PubMed ID: 12829905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
    Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
    Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.
    Parkins MD; Sabuda DM; Elsayed S; Laupland KB
    J Antimicrob Chemother; 2007 Sep; 60(3):613-8. PubMed ID: 17576697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation.
    Shi SH; Lu AW; Shen Y; Jia CK; Wang WL; Xie HY; Zhang M; Liang TB; Zheng SS
    Chin Med J (Engl); 2008 Apr; 121(7):625-30. PubMed ID: 18466683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in invasive disease due to Candida species following heart and lung transplantation.
    Schaenman JM; Rosso F; Austin JM; Baron EJ; Gamberg P; Miller J; Oyer PE; Robbins RC; Montoya JG
    Transpl Infect Dis; 2009 Apr; 11(2):112-21. PubMed ID: 19254327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential risk factors for infection with Candida spp. in critically ill patients.
    Peres-Bota D; Rodriguez-Villalobos H; Dimopoulos G; Melot C; Vincent JL
    Clin Microbiol Infect; 2004 Jun; 10(6):550-5. PubMed ID: 15191384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
    Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
    Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
    Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.
    Safdar A; Hanna HA; Boktour M; Kontoyiannis DP; Hachem R; Lichtiger B; Freireich EJ; Raad II
    Cancer; 2004 Dec; 101(12):2859-65. PubMed ID: 15529309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.
    Magill SS; Swoboda SM; Shields CE; Colantuoni EA; Fothergill AW; Merz WG; Lipsett PA; Hendrix CW
    Ann Surg; 2009 Apr; 249(4):657-65. PubMed ID: 19300221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epidemiological features of Candida infections detected in intensive care units and risk factors affecting mortality].
    Acar A; Oncül O; Küçükardali Y; Ozyurt M; Haznedaroğlu T; Cavuşlu S
    Mikrobiyol Bul; 2008 Jul; 42(3):451-61. PubMed ID: 18822889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome.
    Dimopoulos G; Ntziora F; Rachiotis G; Armaganidis A; Falagas ME
    Anesth Analg; 2008 Feb; 106(2):523-9, table of contents. PubMed ID: 18227310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
    Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
    J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
    Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
    J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
    Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
    Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality.
    Safdar N; Said A; Lucey MR; Knechtle SJ; D'Alessandro A; Musat A; Pirsch J; McDermott J; Kalayoglu M; Maki DG
    Clin Infect Dis; 2004 Aug; 39(4):517-25. PubMed ID: 15356815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
    Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
    Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
    Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
    J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
    Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
    Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.
    Davis SL; Vazquez JA; McKinnon PS
    Ann Pharmacother; 2007 Apr; 41(4):568-73. PubMed ID: 17374623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.